Identification of five lipotoxicity-related genes as prognostic markers for hepatocellular carcinoma based on transcriptomic analyses and experimental validation.
This work has identified a five-gene lipotoxicity-related signature that may facilitate prognostic stratification of patients with HCC and provide a basis for further investigation of lipotoxicity-related prognostic markers.
Abstract
Hepatocellular carcinoma (HCC) is associated with a dismal prognosis. Although lipotoxicity has been shown to promote disease progression through inflammation and oxidative stress, the prognostic value of lipotoxicity-related genes (LTXGs) in HCC remains insufficiently defined. Using public transcriptomic datasets, lipotoxicity-related candidate genes were identified, and prognostic genes were screened by univariate Cox proportional hazards regression, proportional hazards (PH) assumption testing, least absolute shrinkage and selection operator (LASSO) regression, and multivariate Cox regression analyses. A risk-score model was constructed, and a nomogram integrating the risk score and tumor stage was subsequently developed. Functional enrichment analysis, immune infiltration analysis, and reverse-transcription quantitative polymerase chain reaction (RT-qPCR) validation were also performed. Five prognostic genes (SLC2A2, LCAT, PPARGC1A, CDKN2B, and GLP1R) were identified. Gene set enrichment analysis revealed that 35 pathways were differentially enriched between the high- and low-risk groups. Immune infiltration analysis demonstrated significantly higher infiltration of M0 macrophages in the high-risk group. RT-qPCR validation in clinical specimens confirmed that the expression levels of PPARGC1A and SLC2A2 were markedly higher in control tissues than in HCC tissues. This five-gene lipotoxicity-related signature may facilitate prognostic stratification of patients with HCC and provide a basis for further investigation of lipotoxicity-related prognostic markers.
This study presents the first MAM-related prognostic signature specifically tailored to CSCC, filling a gap in existing prognostic models that did not consider the role of MAM.
Wen-Jie Fang, Yi-Fan Zhang, Jie Zhang et al.· Frontiers in Oncology· 0 citations
The findings suggest that SLC5A6 may participate in glucose-deprivation-induced disulfide stress, while its direct role in regulating disulfidptotic cell death remains to be established.
Chong Fu, Ze-Min Fang, Yan-Ping Zhang et al.· Frontiers in Oncology· 0 citations
This work has shown that novel molecular markers with improved sensitivity, specificity, and therapeutic relevance are essential for enhancing early detection and guiding personalized treatment strategies in HCC.
Jana Hamad, Hussein Fayyad-Kazan, F. Abdel-Sater· Cancer Reports· 0 citations
The integrated findings suggest that LOXL2 may possess potential value as both a prognostic biomarker and therapeutic target in lung adenocarcinoma (LUAD), though its clinical translation requires further validation through large-scale prospective studies.
Tie-Gang Cao, G. Qiao, Ming-Dong Ma et al.· Discover Oncology· 0 citations
A robust 4‐MQRG signature comprising ANXA10, BAMBI, AKR1B15, and SPINK1 was established, which revealed that patients classified as high risk had significantly shorter overall survival compared to their low‐risk counterparts, thus offering valuable biomarker support for personalized therapeutic approaches in HCC.
Bin-Bin Li, Li-Jun Zeng, Zhi-Long He et al.· Drug development research (P...· 0 citations
This study establishes a robust LRL-based prognostic model and identifies AC026412.3 as a key regulator of lipid metabolic reprogramming via the SLC22A5–fatty acid β-oxidation axis, highlighting its potential as a biomarker and therapeutic target in HCC.
Li-Xin Liu, Yu-Hao Fan, Hao Zou et al.· Journal of Clinical and Tran...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.